Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

New research shows how alcohol affects heart health in women on hormone therapy. Find out the shocking connection and what ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...